Betamethasone Sodium Phosphate
FDA-approved product (injectable, injection), marketed as Betamethasone Sodium Phosphate, Celestone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Eye inflammation
- Hemorrhoid
- Nasal congestion
- Ulcerative colitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Betamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
NCT00982332 · start 2010-03
Registered record
- Registry ID
- NCT00982332
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Betamethasone; isotonic sodium chloride solution (placebo)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2010-03
- Completion
- 2012-03
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolymyalgia RheumaticaInterventionBetamethasone; isotonic sodium chloride solution (placebo)PhaseNot applicableRegistry statusUnknownComparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder
NCT00914836 · start 2009-06
Registered record
- Registry ID
- NCT00914836
- Conditions
- Tendonitis; Bursitis
- Interventions
- Betamethasone Sodium Phosphate; 1 cc - Betamethasone Sodium Phosphate; 2 cc - Betamethasone Sodium Phosphate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2009-06
- Completion
- 2010-04
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTendonitis; BursitisInterventionBetamethasone Sodium Phosphate; 1 cc - Betamethasone Sodium Phosphate; 2 cc - Betamethasone Sodium PhosphatePhaseNot applicableRegistry statusWithdrawnEvaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee
NCT00542139 · start 2007-12
Registered record
- Registry ID
- NCT00542139
- Conditions
- Osteoarthritis
- Interventions
- Betamethasone; Bupivocaine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2008-11
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritisInterventionBetamethasone; BupivocainePhasePhase 4Registry statusCompletedORTHOVISC Shoulder Osteoarthritis Study
NCT00436969 · start 2006-12
Registered record
- Registry ID
- NCT00436969
- Conditions
- Glenohumeral Osteoarthritis
- Interventions
- Orthovisc; Control
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2011-08
- Enrolment
- 274
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlenohumeral OsteoarthritisInterventionOrthovisc; ControlPhasePhase 3Registry statusCompletedBetamethasone to Control Postoperative Pain in Emergency Endodontic Care
NCT02865746 · start 2004-07
Registered record
- Registry ID
- NCT02865746
- Conditions
- Pain
- Interventions
- Bethametasone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-12
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionBethametasone; PlaceboPhaseNot applicableRegistry statusCompleted